In a research report issued Monday, Brean Capital analyst Jonathan Aschoff maintained a Buy rating on shares of Neuralstem, Inc. (NYSE MKT:CUR), with an $8.
Maxim Group's healthcare analyst Jason Kolbert came out with a negative view on Neuralstem, Inc. (NYSE MKT:CUR), after the company reported its fourth-quarter results and provided …
Brean Capital’s healthcare analyst Jonathan Aschoff weighed in today with a few insights on Neuralstem, Inc. (NYSE MKT:CUR), after the company released its fourth-quarter results and …
In a research note published Thursday, Brean Capital analyst Jonathan Aschoff reiterated a Buy rating on Neuralstem, Inc. (NYSE MKT:CUR) with an $8 price target, after …
In a research report released this morning, Brean Capital analyst Jonathan Aschoff reiterated a Buy rating on Neuralstem, Inc. (NYSE MKT:CUR) with an $8.
